REQUEST A DEMO
Total
USD $0.00
Search more companies

PharmaEngine, Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: PharmaEngine, Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003, and funded by TTY Biopharm and Taiwan venture capitals. PharmaEngine adopts the business model of “no research, development only” and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. In 2003, PharmaEngine licensed the exclusive rights to develop and commercialize PEP02 in Asia from Hermes Biosciences, Inc. (South San Francisco, CA), and subsequently expanded the territory to Europe in 2005.

Headquarters
11F, 10 Minsheng E. Road, Sec. 3
Taipei City; Taipei City;

Contact Details: Purchase the PharmaEngine, Inc. report to view the information.

Website: http://www.pharmaengine.com

Basic Information
Total Employees:
Purchase the PharmaEngine, Inc. report to view the information.
Outstanding Shares:
Purchase the PharmaEngine, Inc. report to view the information.
Financial Auditors:
Purchase the PharmaEngine, Inc. report to view the information.
Incorporation Date:
August 12, 2002
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
17.76%
Purchase this report to view the information.
15.5%
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Formosa Pharmaceuticals, Inc.
0.5%
Company Performance
Financial values in the chart are available after PharmaEngine, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
27.5%
Total operating revenue
27.55%
Operating profit (EBIT)
57.05%
EBITDA
20.35%
Net Profit (Loss) for the Period
53.74%
Total assets
0.93%
Total equity
3.88%
Operating Profit Margin (ROS)
9.32%
Net Profit Margin
9.63%
Return on Equity (ROE)
2.01%
Quick Ratio
3.27%
Cash Ratio
-0.75%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?